NEW YORK (360Dx) – Roche today announced that the US Food and Drug Administration has cleared the company's troponin test for helping diagnose patients suspected of having a heart attack.

The 510(k) clearance makes Roche the first in vitro diagnostic firm in the US to offer the next-generation troponin test for patients as an aid in diagnosing myocardial infarction, enabling doctors to more accurately identify heart attack patients, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.